Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.
Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
Sooi K. et al, (2025), Br J Cancer, 133, 896 - 908
Precision Prevention Studies: A Targeted Approach to Cancer Prevention.
Blagden SP. et al, (2025), Cancer Prev Res (Phila), 18, 499 - 507
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Plummer R. et al, (2025), Cell Rep Med, 6
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.
Liu J. et al, (2025), J Clin Oncol, 43, 735 - 747
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.
Chettle J. et al, (2024), HGG Adv, 5
Access divergence to new cancer medicines in the United Kingdom.
Lythgoe MP. et al, (2024), Eur J Cancer, 207
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Janku F. et al, (2024), Cancers (Basel), 16
Early phase antitumour clinical trials and palliative medicine.
Virani F. et al, (2024), BMJ Support Palliat Care, 13, e780 - e781
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies.
Lythgoe MP. et al, (2023), Lancet Oncol, 24, 963 - 966
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R. et al, (2023), Br J Cancer, 129, 38 - 45
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Luke JJ. et al, (2023), Br J Cancer, 128, 2227 - 2235
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
Lythgoe MP. et al, (2023), Lancet Oncol, 24, e150 - e160